Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
Conditions: Cirrhosis; Cirrhosis, Liver; Cirrhosis Early; Cirrhosis Due to Hepatitis B; Cirrhosis Advanced; Cirrhosis Infectious; Cirrhosis Alcoholic; Cirrhosis, Biliary; Cirrhosis Cryptogenic; Cirrhosis Due to Hepatitis C; Cirrhosis Due to Primary Sclerosing Cholangitis Intervention: Drug: Rosuvastatin Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); The Cleveland Clinic; Columbia University; Weill Medical College of Cornell University; Duke University; Mayo Clinic; University of Miami; University of Michigan; University of Calif ornia, San Diego; University of California, San Francisco; LAC+USC Medical Center; Virginia Commonwealth University; National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Cancer Institute (NCI); University of Southern California Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Alcoholism | Cancer & Oncology | Cirrhosis | Crestor | Diabetes | Endocrinology | Liver | Research | Rosuvastatin | Substance Abuse | Urology & Nephrology | USA Health